Evidence map›Paper›PMID 32925973›Full record

ArticlePLoS pathogens2020

Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5.

Steven W Jin, Francis M Mwimanzi, Jaclyn K Mann, Mwebesa Bosco Bwana, Guinevere Q Lee, Chanson J Brumme, Peter W Hunt, Jeff N Martin, David R Bangsberg, Thumbi Ndung'u and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. SERINC5 counters retroviruses and non-retroviruses.Frontiers in cellular and infection microbiology · 2024
    Review
  11. HIV-1 subtypes maintain distinctive physicochemical signatures in Nef domains associated with immunoregulation.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2023
    Article
  12. Article
  13. Article
  14. HIV-1 restriction by SERINC5.Medical microbiology and immunology · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 6 countries.

Steven W JinFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0003-4091-9954
Francis M MwimanziFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0003-4854-4501
Jaclyn K MannHIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0002-2398-1273
Mwebesa Bosco BwanaFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Guinevere Q LeeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
Chanson J BrummeBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.ORCID 0000-0003-2722-5288
Peter W HuntSchool of Medicine, University of California, San Francisco, United States of America.
Jeff N MartinSchool of Medicine, University of California, San Francisco, United States of America.
David R BangsbergSchool of Public Health, Oregon Health Science University, Portland, United States of America.
Thumbi Ndung'uHIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0002-8157-1037
Mark A BrockmanFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0001-6432-1426
Simon Fraser University · CAUniversity of California, San Francisco · USAIDS Vancouver · CAMbarara University of Science and Technology · UGOregon Health & Science University · USRagon Institute of MGH, MIT and Harvard · USUniversity of British Columbia · CAUniversity of KwaZulu-Natal · ZA

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
NIAID NIH HHS P30 AI027763NIAID NIH HHS UM1 AI126617
6 · The paper itself

Abstract

HIV Nef counteracts cellular host restriction factors SERINC3 and SERINC5, but our understanding of how naturally occurring global Nef sequence diversity impacts these activities is limited. Here, we quantify SERINC3 and SERINC5 internalization function for 339 Nef clones, representing the major pandemic HIV-1 group M subtypes A, B, C and D. We describe distinct subtype-associated hierarchies for Nef-mediated internalization of SERINC5, for which subtype B clones display the highest activities on average, and of SERINC3, for which subtype B clones display the lowest activities on average. We further identify Nef polymorphisms that modulate its ability to counteract SERINC proteins, including substitutions in the N-terminal domain that selectively impair SERINC3 internalization. Our findings demonstrate that the SERINC antagonism activities of HIV Nef differ markedly among major viral subtypes and between individual isolates within a subtype, suggesting that variation in these functions may contribute to global differences in viral pathogenesis.

Indexed as

Polymorphism, GeneticVirus ReplicationHIV-1HIV InfectionsHIV SeropositivityHost-Pathogen InteractionsHumansMembrane GlycoproteinsMembrane Proteinsnef Gene Products, Human Immunodeficiency VirusPrecursor Cell Lymphoblastic Leukemia-LymphomaTumor Cells, CulturedMembrane GlycoproteinsMembrane Proteinsnef Gene Products, Human Immunodeficiency VirusSERINC3 protein, humanSERINC5 protein, human

Identifiers

PMID32925973
PMCPMC7515180
OpenAlexW3085675867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.